
    
      The current study is the second clinical administration with PF-07304814, the phosphate
      prodrug of the active moiety PF-00835231, and the first in healthy adult participants. It is
      to evaluate safety, tolerability and PK of single escalating doses of PF 07304814 given as a
      24-h IV infusion. This is a randomized, double-blind, sponsor-open, placebo-controlled trial.
      There will be 2 cohorts with a total of approximately 16 participants planned (approximately
      8 participants in each cohort).
    
  